CVS - CVS Health Corporation

NYSE - NYSE Delayed Price. Currency in USD
64.22
-5.66 (-8.10%)
At close: 4:01PM EST
Stock chart is not supported by your current browser
Previous Close69.88
Open63.67
Bid0.00 x 1300
Ask0.00 x 800
Day's Range63.30 - 65.19
52 Week Range60.14 - 82.15
Volume43,365,550
Avg. Volume10,301,822
Market Cap83.049B
Beta (3Y Monthly)1.26
PE Ratio (TTM)21.12
EPS (TTM)3.04
Earnings DateFeb 6, 2019 - Feb 11, 2019
Forward Dividend & Yield2.00 (2.86%)
Ex-Dividend Date2019-01-24
1y Target Est88.57
Trade prices are not sourced from all markets
  • CVS stock plummet on disappointing 2019 outlook
    Yahoo Finance Video10 hours ago

    CVS stock plummet on disappointing 2019 outlook

    Shares of the drug store plummeting after reporting lower-than-expected results and a disappointing 2019 outlook. This comes after closing a $70 billion dollar acquisition of Aetna in November. Yahoo Finance's Seana Smith joins Jackie DeAngelis with her take.

  • Stocks end a choppy session higher following Fed meeting minutes
    Yahoo Finance11 hours ago

    Stocks end a choppy session higher following Fed meeting minutes

    U.S. stocks ended in the green as investors digested minutes detailing the deliberations from the Federal Open Market Committee’s latest meeting.

  • Thomson Reuters StreetEvents53 minutes ago

    Edited Transcript of CVS earnings conference call or presentation 20-Feb-19 1:30pm GMT

    Q4 2018 CVS Health Corp Earnings Call

  • Asian stocks change little ahead of more US-China talks
    Associated Press4 hours ago

    Asian stocks change little ahead of more US-China talks

    BEIJING (AP) — Asian stock markets were little-changed Thursday following a listless day on Wall Street ahead of U.S.-Chinese negotiations aimed at ending a tariff battle.

  • The Wall Street Journal7 hours ago

    [$$] CVS Gives Downbeat Earnings Outlook for First Year as Merged Company

    The Woonsocket, R.I.-based company, which in November completed its nearly $70 billion acquisition of insurer Aetna Inc., said that it was taking rapid steps to address the problems, including a cost-cutting effort, and that its ambitious deal positioned it for long-term growth. For 2019, the company said it was projecting adjusted earnings per share of $6.68 to $6.88, compared with analysts’ estimates of $7.41 a share, as polled by Refinitiv. CVS said its results are being hurt by factors including smaller benefits from the rollout of new generic drugs and the performance of Omnicare, its long-term-care pharmacy business.

  • Barrons.com10 hours ago

    The Dow Rises 63 Points Because the Fed Minutes Came and Went

    U.S. stocks closed near the break-even line on Wednesday after the Federal Reserve released the minutes for its January meeting in the afternoon. The minutes were largely consistent with recent public comments made by Federal Open Market Committee members. Markets closed flat as the Fed minutes came largely as expected.

  • Stock Market Today: CVS Battles Headwinds and Tilray Enters the US Hemp Market
    Motley Fool10 hours ago

    Stock Market Today: CVS Battles Headwinds and Tilray Enters the US Hemp Market

    Stocks climbed on optimism about interest rates.

  • TheStreet.com11 hours ago

    CVS Beats Q4 Earnings Forecasts but Guides for Weaker 2019 Profit

    shares closed 8.1% lower Wednesday at $64.22, after it posted stronger-than-expected fourth-quarter earnings but issued 2019 profit guidance that fell far short of Wall Street forecasts linked to "significant additional deterioration" in its long-term care business. CVS Health said adjusted earnings for the three months ending in December came in at $2.14 per share, up 11.5% from the same period last year and firmly ahead of the Street consensus of $2.05 per share. Looking into 2019, CVS said it sees cash flow from operations in the range of $9.8 billion to $10.3 billion and full-year GAAP earnings of between $4.88 and $5.08 per share, or $6.68 to $6.88 on an adjusted basis, well below the Refinitiv forecast of $7.41 per share and the 2018 tally of $7.08 per share.

  • ACCESSWIRE11 hours ago

    INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of CVS Health Corporation (CVS)

    NEW YORK, NY / ACCESSWIRE / February 20, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVS Health Corporation("CVS" or the "Company") ...

  • TheStreet.com11 hours ago

    Dow Rises as Fed Says Growth Risks Cause Pause in Rate Hikes

    The Dow Jones Industrial Average finished higher Wednesday following the release of minutes from the January meeting of the Federal Reserve's rate-setting committee. posted stronger-than-expected fourth-quarter earnings but its 2019 profit guidance fell far short of Wall Street forecasts. said it was replacing its general counsel Dane Butswinkas just two months after he joined the electric carmaker.

  • TheStreet.com11 hours ago

    CVS' Massive M&A Moves Spark Skepticism on the Stock

    "After the payment of our shareholder dividend, capital retention to support our insurance operation and growth capital expenditures of $2.3 billion to $2.6 billion, we will use the remaining cash available to continue to pay down debt," CFO Eva Boratto told analysts. It's no secret that this is largely due to the blockbuster $68 billion deal for major insurer Aetna. The drag of debt payments on this acquisition is a big question mark for 2019 as the insurer seeks integration into the broader CVS brand.